Resmed Inc Q2 Profit Advances

ResMed Inc (RMD.AX) reported stronger Q2 results with GAAP net income of $392.59 million ($2.68/share) versus $344.62 million ($2.34) a year ago and adjusted earnings of $411.47 million ($2.81/share). Revenue rose 10.9% year-over-year to $1.422 billion from $1.282 billion, indicating solid top- and bottom-line growth that should support investor confidence in the company’s fundamentals and market position within medical devices and respiratory care.

Analysis

Market structure: ResMed (RMD) is a clear direct beneficiary — $1.422B revenue (+10.9% YoY) and adjusted EPS $2.81 signal durable demand for sleep-disordered breathing devices and connected-care software. Smaller CPAP rivals and grey-market/used-device sellers are the losers as stronger growth sustains pricing power and recurring consumables revenue; expect 100–300bp improvement in gross leverage on installed-base monetization over 12–24 months if trends persist. Cross-asset: modest positive for defensive healthcare equity flows, slight downward pressure on healthcare credit spreads if margins expand; expect options implied vol to compress ~20–40% within weeks post-earnings if guidance is stable.

Risk assessment: Top tail risks are a CMS reimbursement cut (a 5–10% device price cut would shave ~3–7% off RMD revenue), a product recall/litigation shock, or component shortages. Immediate (days) risk is an earnings-driven pop/reversion; short-term (weeks–months) hinges on guidance and CMS commentary; long-term (quarters–years) depends on SaaS upsell and international penetration. Hidden dependencies include dealer networks, mask consumable attach rates (material recurring revenue), and software regulatory approvals; catalysts: next 90–180 days of guidance, CMS rulemaking, and analyst revisions.

Trade implications: Direct: consider establishing a 2–4% long position in RMD (ticker RMD) now, layering in on any pullback >5% within 1–3 months; set stop-loss at 8% and take-profit at 12–20% within 3–6 months. Options: buy a 6-month call spread (buy 10% ITM, sell 30% OTM) to cap cost and capture upside, or sell short 30-day calls post-IV compression if holding stock. Pair trade: long RMD vs short Philips (PHIA/PHG) 1:1 for relative exposure to CPAP share gains.

Contrarian angles: Consensus may underweight reimbursement/regulatory risk and overestimate saturation in developed markets; conversely it may under-appreciate SaaS margin expansion — a 2–4ppt operating margin tailwind over 12–24 months could re-rate the stock by 10–25%. Near-term rally could be overdone; implement covered-call overlays (30–60 day) if implied vols are rich, and reduce exposure if next-quarter revenue guidance is cut >3% or adjusted EPS guidance misses by >5%.

Key Decisions for Investors

• Establish a 2–4% long position in ResMed (RMD) within 5 trading days; add up to +1–2% on any pullback >5% within the next 1–3 months. Set stop-loss at 8% and plan to take profits at 12–20% gain within 3–6 months.
• Buy a 6-month call spread on RMD (buy 10% ITM, sell 30% OTM) sized to equal 1–2% portfolio risk to capture upside while limiting premium outlay; unwind if implied vol compresses >30% or guidance misses by >5%.
• Implement a pair trade: long RMD / short Philips (PHIA or PHG) equal dollar exposure to isolate CPAP market-share dynamics; trim pair if RMD guidance is cut >3% or PHIA announces major remediation success.
• If holding RMD into earnings-driven volatility, sell 30–60 day covered calls to monetize near-term IV (strike ~5–8% OTM); avoid naked short calls. Reduce position if CMS signals a reimbursement cut >=5% or adjusted EPS guidance falls >5% QoQ.